@entity310 gene polymorphisms and XXXX : Influence on disease outcome and therapeutic response.

@entity310 @entity1 @entity15646 @entity4932
OBJECTIVE: To investigate the genetic contribution of @entity310 gene polymorphisms on the disease course and therapeutic response in @entity1 with @entity4932 ( @entity4932 ). METHODS: 74 Caucasian @entity1 with @entity4932 were recruited with a control group of 77 healthy @entity1 . DNA was extracted for analysis of @entity310 gene promoter polymorphisms at positions -163, -244, -238, -376, and -308. RESULTS: No SNPs at position -163 were observed, while we observed only SNPs at positions -244 and -376 in the controls. No differences were observed in the prevalence of SNPs at -238 and -308 between @entity4932 and controls. In @entity4932 @entity1 no significant differences were observed between the -238 and @entity15646 genotypes and different disease phenotypes. We observed a significant lower disease activity expressed in the carriers of -308 GG genotype with respect to GA and AA genotypes after 6 (p = 0.008 and p = 0.013, respectively) and 12 months of disease (p = 0.02 and p = 0.08, respectively). Also the -238 GG genotypes showed a better disease course after 12 months of disease. Moreover, the -238/-308 GG genotypes presented the higher reduction of disease activity both after 6 (p < 0.01 vs GA and p < 0.01 vs AA) and 12 months from baseline (p < 0.01 vs GA and p < 0.01 vs AA). After 12 months of biologic therapy, a significant higher disease activity was observed in @entity1 with genotype -308 AA respect to both GA (p = 0.012) and GG (p = 0.016). CONCLUSIONS: @entity4932 @entity1 carrying the @entity310 -308 GA/AA and -238 GA genotypes are associated with a worse prognosis and with a lower response to anti- @entity310 drugs.
